Immediate Impact
1 from Science/Nature 30 standout
Citing Papers
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
Targeted protein degradation: advances in drug discovery and clinical practice
2024 Standout
Works of Jonas Ristau being referenced
EML4‐ALK fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non‐small cell lung cancer
2018
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Jonas Ristau | 160 | 94 | 90 | 184 | 113 | 19 | 343 | |
| Sébastien Vauclin | 69 | 58 | 89 | 161 | 194 | 13 | 334 | |
| L.M. Keller | 75 | 62 | 63 | 100 | 89 | 14 | 336 | |
| Kerstin Brüchner | 137 | 79 | 27 | 93 | 107 | 16 | 382 | |
| Peter Geyer | 146 | 73 | 43 | 69 | 133 | 26 | 387 | |
| Eduardas Aleknavičius | 77 | 43 | 50 | 96 | 87 | 33 | 372 | |
| Veronica Cox | 84 | 33 | 127 | 99 | 35 | 20 | 344 | |
| Jonathan Kuten | 239 | 17 | 77 | 141 | 184 | 23 | 396 | |
| Haider Shirazi | 85 | 37 | 62 | 116 | 45 | 12 | 345 | |
| Takuya Kaminuma | 217 | 92 | 61 | 89 | 101 | 35 | 370 | |
| Kevin Lee Min Chua | 198 | 36 | 37 | 130 | 63 | 30 | 316 |
All Works
Login with ORCID to disown or claim papers
Loading papers...